


WEEKLY BULLETIN


Market Trend



The long weekend didn't move the investors and overall activity remained thin. SOFIX lost 0.82% since the beginning of April but the index's components stayed aside of the market attention except several block deals. Compensation bonds, mainly BLKD and BLKB, stayed in focus after a large package transaction at the end of March. The deal for 10.15 million Compensation bonds under the CONP Act (BLKD) improved the speculative interest and the position increased.

The overall picture remained the same as in the previous month. Weak activity and mainly institutional investors' participation.

Trading Activity



The overall volumes received support mainly from ELARG Agricultural Land Opportunity Fund REIT (4EC) and some other REIT companies. The obligation for dividend payment turned the focus toward these companies. The forthcoming liquidation of ELARG increased the traded volume on the position since the beginning of March. Deals for totally 280 000 shares of Sopharma (3JR) boosted the SOFIX's volume on Wednesday.



WEEKLY BULLETIN

SOFIX's Components

05 April 2013

SOFIX

SUFIX'S Components				
Stock	Last Price	Weekly Change	Bid	Ask
Advance Terrafund REIT	2.66	0.42%	2.64	2.66
Albena	44.00	-2.22%	43.50	44.44
Bulgaria Real Estate Fund REIT	0.62	4.59%	0.61	0.62
Bulgartabac Holding	85.00	0.00%	82.90	85.00
Central Cooperative Bank	0.84	-4.89%	0.84	0.86
Chimimport	1.24	-5.00%	1.23	1.25
M+S Hydraulic	6.65	0.76%	6.66	6.90
Eurohold Bulgaria	0.96	-0.31%	0.91	0.96
First Investment Bank	1.76	0.40%	1.75	1.76
Industrial Holding Bulgaria	0.72	-0.96%	0.72	0.75
Kaolin	3.50	-4.05%	3.50	3.66
Monbat	6.20	1.47%	6.20	6.29
Sopharma	2.38	0.04%	2.36	2.38
Stara Planina Hold	2.47	0.00%	2.47	2.60
Zarneni Hrani	0.37	-6.35%	0.37	0.38

Most of the SOFIX's components closed on the downside. Zarneni Hrani Bulgaria (T43) and its parent company Chimimport (6C4) underperformed in low volumes. The banking sector closed mixed. Central Cooperative Bank (4CF) finished by almost 5% down, whereas First Investment Bank (5F4) was almost flat. However, most of the components were trade in insignificant volumes as were aside of the market's attention.

News

- 01 April 2013: Due to unforeseen delays related to the completion of the audit of the annual financial report of Monbat (5MB) by the newly elected registered auditor and the impossibility to comply with the deadline for submission of the report, we would like to inform you of the following: The corporate board of the company will present the audited annual financial statements of Monbat immediately after the sign-off by our certified external group auditor but in any event, not later than April 8, 2013. The corporate board of Monbat would like to express its belief that investors and all of the institutions on the capital market will show understanding in view of the fact that the company has repeatedly proven its responsibility towards investors and has consistently applied a transparent policy in its relations with all participants on the capital market.
- O4 April 2013: Sopharma (3JR) hereby notify that from March 28 2013 to April 03 2013 the Company has bought back 1 000 own shares at the total value of BGN 2 370 as the average repurchase price has been BGN 2.37 per share.

The shares have been bought back on the grounds of a decision of the General Meeting dated June 23 2010.

The total number of bought-back shares after this transaction has reached 3 667 347 shares, representing 2.778% of the share capital of the Company.



WEEKLY BULLETIN

05 April 2013

Disclaimer

Analyst Certification: The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

Financial Interest: ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

Regulatory Authority: Financial Supervisory Commission, Shar Planina Street 33, 1303 Sofia, Bulgaria

Information Disclosure: All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

Risks for Investors: Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments

Valuation Methods: Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

Recommendations: Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

Outperform	More than 5% higher as compared to SOFIX and BG40 performance
Market Perform	Market performance, +/-5% as compared to SOFIX and BG40
Underperform	More than 5% lower as compared to SOFIX and BG40 performance

Frequency of Recommendations: No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

For more information, please contact:

Research analyst Phone: E-mail: Internet:
Tsvetoslav Tsachev +359 2 810 00 23 tsachev@elana.net www.elana.net
Tamara Becheva +359 2 810 00 27 becheva@elana.net www.elana.net